[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 43 of about 43
1. Sevinir B, Ozkan TB: Infantile hepatic hemangioendothelioma: clinical presentation and treatment. Turk J Gastroenterol; 2007 Sep;18(3):182-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile hepatic hemangioendothelioma: clinical presentation and treatment.
  • BACKGROUND/AIMS: Hepatic hemangioendotheliomas are rare tumors in childhood.
  • METHODS: This retrospective analysis included eight patients with infantile hepatic hemangioendothelioma.
  • RESULTS: The median age at diagnosis was 24 days (age range: 1 to 70 days) and the female/male ratio was 5/3.
  • Four cases had single hepatic tumors while the others had multiple.
  • These lesions were located equally in the right and left hepatic lobes, and three babies had bilobar involvement.
  • Most of the multifocal hepatic tumors were associated with skin hemangiomas.
  • Treatment options were assessed individually.
  • Systemic prednisolone therapy (2 mg/kg/d) was commenced in six patients.
  • One boy with Kasabach-Merritt syndrome did not respond to this therapy.
  • Interferon-alpha (1 million units (MU)/m2/day) was started, and the daily dose of the drug was increased up to 10 MU/m2, administered 3 times per week, until clinical improvement was achieved.
  • CONCLUSIONS: The treatment approaches depend on the center's experience.
  • A multidisciplinary approach is required for the best treatment option.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Abdomen. Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Dilatation, Pathologic / etiology. Female. Glucocorticoids / therapeutic use. Hemangioma / diagnosis. Hepatomegaly / etiology. Humans. Immunologic Factors / therapeutic use. Infant. Infant, Newborn. Interferon-alpha / therapeutic use. Male. Neoplasms, Multiple Primary. Prednisolone / therapeutic use. Respiratory Distress Syndrome, Newborn / etiology. Retrospective Studies. Skin Neoplasms / diagnosis. Turkey / epidemiology

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891692.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunologic Factors; 0 / Interferon-alpha; 9PHQ9Y1OLM / Prednisolone; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


2. Al-Tonbary Y, Fouda A: Infantile hepatic hemangioendothelioma: an 8-month old infant successfully treated with a corticosteroid. Hematol Oncol Stem Cell Ther; 2009;2(3):422-5
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile hepatic hemangioendothelioma: an 8-month old infant successfully treated with a corticosteroid.
  • Infantile hemangioendothelioma is a rare benign vascular tumor of the liver.
  • We report a case of hepatic hemangioendothelioma in an 8- month-old female infant who presented with hepatomegaly and respiratory distress, which was successfully treated with oral prednisolone for six months.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Hemangioendothelioma / drug therapy. Liver Neoplasms / drug therapy. Prednisolone / therapeutic use
  • [MeSH-minor] Female. Humans. Infant. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139057.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


3. Gupta R, Mathur SR, Gupta SD, Durgapal P, Iyer VK, Das CJ, Shalimar, Acharya SK: Hepatic epithelioid hemangioendothelioma: A diagnostic pitfall in aspiration cytology. Cytojournal; 2010;6:25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic epithelioid hemangioendothelioma: A diagnostic pitfall in aspiration cytology.
  • Hepatic epithelioid hemangioendothelioma (EH) is a rare vascular neoplasm.
  • An accurate radiologic diagnosis is usually difficult due to the presence of multiple nodules, simulating metastatic carcinoma.
  • Though histologic features of this tumor are well described, cytologic reports of hepatic EH are very few in the available literature.
  • We describe a case of a young healthy adult male who was found to have multiple hepatic masses on radiologic investigations.
  • The diagnosis was made on core biopsy assisted by immunohistochemistry, which showed characteristic features of EH.
  • He is doing well 14 months after diagnosis, without surgical excision or chemotherapy.
  • An accurate diagnosis of hepatic EH on aspiration cytology requires an adequate specimen and awareness of its cytologic features, including discohesive atypical cells with intracytoplasmic lumina and intranuclear inclusions.
  • Since this tumor is usually unresectable but has a favorable prognosis as compared to hepatocellular carcinoma, a correct diagnosis is essential for appropriate management and prognostication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1990 Feb;21(2):212-7 [1689691.001]
  • [Cites] Diagn Cytopathol. 1989;5(2):207-10 [2776603.001]
  • [Cites] Gastroenterology. 1988 Jun;94(6):1447-53 [3282968.001]
  • [Cites] Acta Cytol. 1986 Mar-Apr;30(2):194-200 [3515816.001]
  • [Cites] Acta Cytol. 2008 Nov-Dec;52(6):713-7 [19068677.001]
  • [Cites] Diagn Cytopathol. 1997 Jul;17(1):50-3 [9218904.001]
  • [Cites] Acta Cytol. 1997 Sep-Oct;41(5):1468-76 [9305386.001]
  • [Cites] J Clin Pathol. 1997 Dec;50(12):1029-31 [9516888.001]
  • [Cites] AJR Am J Roentgenol. 2006 Nov;187(5):W481-9 [17056878.001]
  • [Cites] Hum Pathol. 1984 Sep;15(9):839-52 [6088383.001]
  • (PMID = 20165548.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2822180
  • [Keywords] NOTNLM ; Aspiration cytology / epithelioid hemangioendothelioma (EH) / histopathology / immunohistochemistry / liver
  •  go-up   go-down


Advertisement
4. Raphael C, Hudson E, Williams L, Lester JF, Savage PM: Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report. J Med Case Rep; 2010;4:413
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report.
  • INTRODUCTION: Hepatic epithelioid hemangioendothelioma is a rare malignancy arising from the vascular endothelial cells within the liver.
  • Historically, the disease is characterized as being poorly responsive to both chemotherapy and radiotherapy, with liver resection or transplantation the treatment of choice when feasible.
  • For patients with advanced disease, reports of long-term therapeutic benefits from conventional cytotoxic treatments are very limited.
  • Owing to the rarity of this malignancy, there is no structured therapeutic research, but a small number of cases have been reported to respond well to treatment with inhibitors of angiogenesis.
  • Thalidomide was originally developed as an anti-emetic but is a potent inhibitor of vascular neogenesis, and could offer potential in the treatment of hepatic epithelioid hemangioendothelioma by blocking the proliferation of the malignant vascular endothelial cells.
  • CASE PRESENTATION: We describe the case of a Caucasian British woman who presented at the age of 53 years with a hepatic mass, malignant lymphadenopathy and pulmonary metastases, which were confirmed as hepatic epithelioid hemangioendothelioma on biopsy.
  • After unproductive treatment with interferon, our patient was started on thalidomide 400 mg daily.
  • She has been successfully managed on this therapy for the past seven years, and has remained asymptomatic, with radiologically stable disease and minimal treatment-related side effects.
  • CONCLUSION: At present, there is no standard therapy for advanced hepatic epithelioid hemangioendothelioma.
  • Our case supports the role for thalidomide and potentially other inhibitors of vascular neogenesis in the treatment of patients with metastatic hepatic epithelioid hemangioendothelioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2004;67(5-6):471-5 [15714004.001]
  • [Cites] Oncologist. 2005 Apr;10(4):269-81 [15821247.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2108-21 [17019735.001]
  • [Cites] J Neurooncol. 2010 Apr;97(2):275-7 [19898746.001]
  • [Cites] Hum Pathol. 1984 Sep;15(9):839-52 [6088383.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2607-9 [12039920.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):949-57; discussion 957 [18043096.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Jul;30(7):550-2 [18797205.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):970-81 [7093931.001]
  • [Cites] Ann Dermatol Venereol. 1994;121(12):898-904 [7632008.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):171-5 [9075791.001]
  • (PMID = 21176188.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022673
  •  go-up   go-down


5. Chen CC, Kong MS, Yang CP, Hung IJ: Hepatic hemangioendothelioma in children: analysis of thirteen cases. Acta Paediatr Taiwan; 2003 Jan-Feb;44(1):8-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic hemangioendothelioma in children: analysis of thirteen cases.
  • Hepatic hemangioendothelioma (HE) is a tumor that presents in infancy and toddler.
  • The diagnosis was made by the histology specimen or various imaging studies.
  • Abdominal ultrasonography (n = 13) showed heterogeneous and hypoechoic lesions in the liver.
  • Computed tomography (n = 11) revealed central hypointensity with peripheral enhancement after contrast of the liver masses.
  • Magnetic resonance imaging studies of the hepatic masses (n = 3) showed decreased signal intensity on T1 images and high signal intensity on T2.
  • Other management included interferon, chemotherapy, embolization and/or surgery.
  • Among the other nine patients, four patients died of sepsis, hepatic failure, disseminated intravascular coagulopathy or tumor rupture with hemorrhagic shock.
  • For its management, steroid is a first-line medication.
  • Other methods of treatment were interferon, hepatic artery embolization, chemotherapy and surgery.
  • Long term follow up is needed for the evaluation of treatment response.
  • [MeSH-major] Hemangioendothelioma / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12800377.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


6. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J: Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer; 2006 Nov 1;107(9):2108-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.
  • Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown etiology and a variable natural course.
  • The authors present a comprehensive review of the literature on HEH with a focus on clinical outcome after different therapeutic strategies.
  • The reviewed parameters included demographic data, clinical manifestations, therapeutic modalities, and clinical outcome.
  • Most patients presented with multifocal tumor that involved both lobes of the liver.
  • Lung, peritoneum, lymph nodes, and bone were the most common sites of extrahepatic involvement at the time of diagnosis.
  • The most common management has been liver transplantation (LTx) (44.8% of patients), followed by no treatment (24.8% of patients), chemotherapy or radiotherapy (21% of patients), and liver resection (LRx) (9.4% of patients).
  • The 1-year and 5-year patient survival rates were 96% and 54.5%, respectively, after LTx; 39.3% and 4.5%, respectively, after no treatment, 73.3% and 30%, respectively, after chemotherapy or radiotherapy; and 100% and 75%, respectively, after LRx.
  • LRx has been the treatment of choice in patients with resectable HEH.
  • However, LTx has been proposed as the treatment of choice because of the hepatic multicentricity of HEH.
  • The role of different adjuvant therapies for patients with HEH remains to be determined.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / diagnosis. Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Female. Hepatectomy. Humans. Liver Transplantation. Male. Neoplasm Metastasis. Survival Rate

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 17019735.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


7. Kalpatthi R, Germak J, Mizelle K, Yeager N: Thyroid abnormalities in infantile hepatic hemangioendothelioma. Pediatr Blood Cancer; 2007 Dec;49(7):1021-4
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid abnormalities in infantile hepatic hemangioendothelioma.
  • We report an infant with hepatic hemangioendothelioma (HAE) associated with compensated hypothyroidism.
  • The hepatic lesions regressed with steroid therapy and his thyroid function normalized with high doses of thyroxine supplement.
  • [MeSH-major] Hemangioendothelioma / complications. Hypothyroidism / complications. Liver Neoplasms / complications. Thyroxine / therapeutic use
  • [MeSH-minor] Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Heart Failure / complications. Heart Failure / drug therapy. Humans. Male. Steroids / therapeutic use. Thyroid Function Tests. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 16544297.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


8. Emamaullee JA, Edgar R, Toso C, Thiesen A, Bain V, Bigam D, Kneteman N, Shapiro AM: Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management. Liver Transpl; 2010 Feb;16(2):191-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.
  • Epithelioid hemangioendothelioma (EHE) is a low-grade, malignant vascular tumor that most commonly presents within the liver.
  • Patients with hepatic EHE are often candidates for liver transplantation as the disease is usually multifocal at diagnosis.
  • Although these patients achieve excellent early outcomes post-transplant, there are very few data regarding tumor markers that can further direct chemotherapy in hepatic EHE to prevent recurrent disease.
  • The purpose of this study was to analyze the expression of the angiogenic factor vascular endothelial growth factor (VEGF) and its receptors in hepatic EHE.
  • Six patients with hepatic EHE were assessed for liver transplantation at our center.
  • Pathology specimens of primary and recurrent EHE were analyzed by hematoxylin and eosin staining and by immunofluorescence for VEGF, fetal liver kinase 1 (Flk-1), and fms-related tyrosine kinase 1 (Flt-1) expression.
  • Five patients underwent liver transplantation, and 1 patient underwent liver resection.
  • In 1 patient with recurrent hepatic EHE post-liver transplantation, a progressive increase in the VEGF fluorescence intensity and distribution was observed.
  • In conclusion, in this series, VEGF expression was observed in all hepatic EHE specimens analyzed.
  • These data suggest that anti-VEGF chemotherapeutic agents will be of use in patients with hepatic EHE, particularly as a means of reducing the tumor volume prior to resection, as a means of treating unresectable or metastatic disease, or as an adjuvant therapy in the setting of liver transplantation.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / metabolism. Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / metabolism. Liver Neoplasms / surgery. Liver Transplantation. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Adult. Angiogenesis Inhibitors / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Retrospective Studies. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104492.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


9. Walsh R, Harrington J, Beneck D, Ozkaynak MF: Congenital infantile hepatic hemangioendothelioma type II treated with orthotopic liver transplantation. J Pediatr Hematol Oncol; 2004 Feb;26(2):121-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital infantile hepatic hemangioendothelioma type II treated with orthotopic liver transplantation.
  • The authors describe a 10-week-old girl with infantile hepatic hemangioendothelioma who initially presented with difficulty feeding, hepatomegaly, and multiple hemangiomas of the skin.
  • Six weeks of steroid therapy and 2 weeks of chemotherapy failed to produce clinical improvement.
  • The patient underwent split liver transplantation.
  • A definitive diagnosis of hemangioendothelioma type II was made.
  • Imaging studies cannot differentiate between hemangioendothelioma and angiosarcoma.
  • Treatment modalities for this condition remain unclear.
  • [MeSH-major] Hemangioendothelioma / congenital. Hemangioendothelioma / surgery. Liver Neoplasms / congenital. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Female. Humans. Infant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14767204.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / 1012HP000222
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


10. Grabhorn E, Richter A, Fischer L, Krebs-Schmitt D, Ganschow R: Neonates with severe infantile hepatic hemangioendothelioma: limitations of liver transplantation. Pediatr Transplant; 2009 Aug;13(5):560-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonates with severe infantile hepatic hemangioendothelioma: limitations of liver transplantation.
  • IHHE as the most common vascular tumor of the liver in infancy can present with acute postnatal liver and congestive heart failure.
  • Here we discuss the benefit of LTx in cases of acute postnatal deterioration and massive extent of the hepatic tumor.
  • Two were neonates with acute postnatal decompensation and progressive liver and heart failure within days.
  • Treatment with steroids and chemotherapy was ineffective; resection surgery and interventional treatment were not considered appropriate.
  • Patients 1 and 2 had to be resuscitated during the LTx procedure because of massive bleeding and both died during the procedure.
  • Neonates with extended hepatic and extrahepatic involvement of IHHE should be evaluated carefully prior to LTx.
  • Whenever possible, alternative interventional treatment options should be considered.
  • [MeSH-major] Hemangioendothelioma / therapy. Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Female. Humans. Infant, Newborn. Male. Steroids / therapeutic use. Time Factors. Treatment Outcome


11. Haberal M, Ozcay F, Sevmis S, Karakayali H, Moray G, Torgay A, Coskun M, Demirhan B, Sarialioglu F, Arslan G: Liver transplant in an infant with bilateral cystic neuroblastoma complicated by hepatic metastases and life-threatening consumption coagulopathy. Pediatr Transplant; 2008 May;12(3):358-62
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplant in an infant with bilateral cystic neuroblastoma complicated by hepatic metastases and life-threatening consumption coagulopathy.
  • Here we report a patient with stage-4 bilateral cystic adrenal neuroblastomas with disseminated liver metastases and consumption coagulopathy who underwent liver transplant.
  • Our patient was initially diagnosed with infantile hepatic hemangioendothelioma and bleeding into the adrenal glands secondary to consumption coagulopathy (Kasabach-Merritt syndrome).
  • Liver transplant was performed as a life-saving procedure under this diagnosis.
  • We discuss this unique patient because of the diagnostic pitfalls of this rare disease and the successful clinical outcome after LT and subsequent chemotherapy for neuroblastoma.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Disseminated Intravascular Coagulation / therapy. Liver Neoplasms / pathology. Liver Transplantation / methods. Neuroblastoma / pathology
  • [MeSH-minor] Adrenal Glands / pathology. Antineoplastic Agents / therapeutic use. Female. Humans. Infant. Living Donors. Neoplasm Metastasis. Treatment Outcome


12. Le Luyer B, Duquenoy A, Poinsot J, Boulloche J, Gaussin G, Le Roux P: [Use of interferon in a case of hepatic hemangioma]. Arch Pediatr; 2000 Nov;7(11):1201-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of interferon in a case of hepatic hemangioma].
  • Hepatic hemangioendothelioma can have a fatal outcome.
  • After failure of classic therapies, and when surgery or arterial embolization are not possible, those benign tumours may benefit from interferon alpha treatment.
  • CASE REPORT: We report a case of a 14-month-old infant who presented with hepatic hemangiomatosis and cardiac failure.
  • The disease can neither be controlled by steroids nor by radiotherapy associated with digitalo-diuretic treatment.
  • CONCLUSION: Interferon alpha treatment helps to control cardiac failure and the course of hepatic hemangioma in childhood.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioendothelioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Infant. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109948.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


13. Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, Garzon MC: Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics; 2006 Sep;118(3):e907-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature.
  • Multiple cutaneous hemangiomas can be associated with internal hemangiomas, with the liver being the most common site.
  • Here we report a case of a premature female neonate who presented with cardiac failure at birth and had typical-appearing infantile hemangiomas on the skin in association with vascular lesions in the liver.
  • Her clinical presentation was felt to be consistent with cutaneous and hepatic infantile hemangiomas.
  • After failure to respond to systemic steroids and chemotherapy, she underwent liver transplantation.
  • Histopathologic evaluation of the liver revealed a diagnosis of type 2 infantile hepatic hemangioendothelioma (regarded as synonymous with angiosarcoma) rather than benign infantile hemangioma of the liver.
  • We report this case and a review of the literature on pediatric angiosarcoma of the liver associated with cutaneous infantile hemangiomas.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Heart Defects, Congenital. Humans. Infant, Newborn. Liver Transplantation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatrics. 2007 Jun;119(6):1271
  • (PMID = 16880251.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


14. Biecker E, Fischer HP, Strunk H, Sauerbruch T: Benign hepatic tumours. Z Gastroenterol; 2003 Feb;41(2):191-200
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign hepatic tumours.
  • Benign hepatic tumours include a broad spectrum of regenerative and true neoplastic processes.
  • Due to advances in imaging procedures like MRI, Cf-scan and ultrasound as well as progress in immunohistochemistry, the appropriate diagnosis is made ina high percentage of patients without laparotomy and resection.
  • Most important in clinical practice is the differential diagnosis of focal nodular hyperplasia and hepatocellular adenoma because of the risk of rupture and bleeding in the latter.
  • Cavernous haemangioma, the most common benign hepatic tumour, rarely needs treatment.
  • The diagnosis of nodular regenerative hyperplasia is often missed and patients present with secondary complications and signs of portal hypertension that necessitate treatment.
  • The main problem in angiomyolipoma is to distinguish it from malignant processes which do require treatment.
  • Because of its clinical presentation, inflammatory pseudotumour is also sometimes confused with a malignant tumour.
  • Therapeutic options are drug therapy or surgical resection.
  • [MeSH-major] Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Adult. Aged. Diagnostic Imaging. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / pathology. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / pathology. Humans. Infant. Liver / pathology. Liver Regeneration / physiology. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650132.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 138
  •  go-up   go-down


15. Schilling G, Schuch G, Panse JP, Sterneck M, Bokemeyer C: Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report.
  • : e21527 Background: HEH is a rare tumor of the liver with an unpredictable malignant potential.
  • Surgical resection or liver transplantation is recommended in locally advanced disease and has been successfully performed in selected cases with extrahepatic manifestations.
  • Systemic therapy, however, is not standardized.
  • Small cohorts have been treated with interferon, chemotherapy and angiogenesis inhibitors such as thalidomide with various results.
  • CASE REPORT: A 33-year old caucasian previously healthy male was admitted to hospital with newly diagnosed suspicious lesions in liver and spleen.
  • Disease progressed during first line treatment with adriamycin and ifosfamide (2 cycles given).
  • Retrospective analysis after 9 cycles demonstrated stable disease in comparison to the recent investigation, but an overall progression of 22% according to RECIST criteria in the liver was observed.
  • Due to the excellent tolerance we increased the daily dose to 30 mg (21/28) and 6 months later a slight regression in the lung and overall stable disease in the liver was observed.
  • The patient was listed for liver transplantation and after another 4 months on lenalidomide 30 mg, he was successfully transplanted recently.
  • Because of the remaining extrahepatic lesions it is planned to continue lenalidomide therapy in combination with the immunosuppressant rapamycine.
  • CONCLUSIONS: We report the first case of successful therapy with lenalidomide in HEH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963457.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Uchimura K, Nakamuta M, Osoegawa M, Takeaki S, Nishi H, Iwamoto H, Enjoji M, Nawata H: Hepatic epithelioid hemangioendothelioma. J Clin Gastroenterol; 2001 May-Jun;32(5):431-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic epithelioid hemangioendothelioma.
  • Epithelioid hemangioendothelioma (EHE) is a rare neoplasm of vascular origin with unpredictable malignant potential.
  • We describe two patients with primary EHE of the liver and review 34 cases previously published in Japan and compare them with those in Western countries.
  • The clinical aspects of EHE and relevant treatment results in Japanese patients were similar to those found in Western countries, the exception being the matter of difference in incidence between genders.
  • Although this tumor type has been reported to be more frequent among women, there was no significant difference in incidence between men and women.
  • Hepatic EHE generally behaves as a low-grade malignant tumor with a slow progression phenotype; however, this disease seems to be resistant to chemotherapy and to be lethal in some cases.
  • Surgical resection or liver transplantation is recommended after rapid diagnosis by radiologic examination and histologic findings, including positive staining of tumor cells for factor VIII-related antigen.
  • [MeSH-major] Hemangioendothelioma, Epithelioid. Liver Neoplasms
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11319317.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 7
  •  go-up   go-down


17. Mehrabi A, Kashfi A, Schemmer P, Sauer P, Encke J, Fonouni H, Friess H, Weitz J, Schmidt J, Büchler MW, Kraus TW: Surgical treatment of primary hepatic epithelioid hemangioendothelioma. Transplantation; 2005 Sep 27;80(1 Suppl):S109-12
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of primary hepatic epithelioid hemangioendothelioma.
  • Epithelioid hemangioendothelioma is a very rare tumor of vascular origin.
  • It can develop in different tissues such as soft tissue, lung, or liver.
  • Hepatic epithelioid hemangioendothelioma (HEH) mostly affects females.
  • The malignant potential of HEH often remains unclear in the individual patient.
  • It can range from benign hemangioma to malignant hemangioendotheliosarcoma.
  • All patients in our series with confirmed histological HEH did not show extrahepatic extension and consequently underwent surgical treatment.
  • In three patients, liver transplantation (LTx) was performed (two cadaveric and one living related).
  • No adjuvant chemotherapy was applied.
  • Early detection and surgical intervention in case of HEH can potentially offer curative treatment.
  • The treatment of first choice appears to be radical liver resection.
  • Despite the long waiting time, its often unclear dignity, and a proven progressive growth pattern, living related LTx also plays a potentially important role.
  • Long-term survival of patients with HEH is significantly higher compared to other hepatic malignancies.
  • The role of adjuvant therapy currently remains unclear.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Retrospective Studies. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286886.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mascarenhas RC, Sanghvi AN, Friedlander L, Geyer SJ, Beasley HS, Van Thiel DH: Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology; 2004;67(5-6):471-5
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
  • Hepatic epithelioid hemangioendothelioma (HEH) is a rare vascular tumor of the liver with an unpredictable malignant potential.
  • Its growth can lead to hepatic failure, extrahepatic metastasis and death.
  • Surgical resection or liver transplantation is the treatment of choice if metastasis is not identified.
  • We report the case of a 52-year-old patient with HEH metastatic to the lungs who was successfully treated with oral thalidomide therapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Hemangioendothelioma, Epithelioid / drug therapy. Hemangioendothelioma, Epithelioid / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Thalidomide / therapeutic use
  • [MeSH-minor] Disease Progression. Drug Administration Schedule. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel
  • (PMID = 15714004.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


19. Kassam A, Mandel K: Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl. J Pediatr Hematol Oncol; 2008 Jul;30(7):550-2
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
  • SUMMARY: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare malignant tumor characterized by its epithelioid structure and vascular endothelium origin.
  • The clinical course of HEHE is variable, ranging from long-term survival without treatment to a rapidly progressive course with a fatal outcome.
  • As a consequence, no standard treatment has been determined.
  • We present a case of HEHE occurring in a 13-year-old girl, in which a novel treatment approach using antiangiogenic therapy was tried and was successful in slowing the progression of the disease.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / secondary. Liver Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Adolescent. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Celecoxib. Cisplatin / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Therapy, Combination. Female. Humans. Interferon-alpha / therapeutic use. Liver Failure / etiology. Liver Failure / surgery. Liver Transplantation / ethics. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / etiology. Pyrazoles / administration & dosage. Pyrazoles / therapeutic use. Recombinant Proteins. Sulfonamides / administration & dosage. Sulfonamides / therapeutic use. Thalidomide / administration & dosage. Thalidomide / therapeutic use. Vinblastine / administration & dosage. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797205.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interferon-alpha; 0 / Pyrazoles; 0 / Recombinant Proteins; 0 / Sulfonamides; 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine; 76543-88-9 / interferon alfa-2a; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Calabrò L, Di Giacomo AM, Altomonte M, Fonsatti E, Mazzei MA, Volterrani L, Miracco C, Maio M: Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res; 2007 Mar;26(1):145-50
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments?
  • Primary hepatic epithelioid hemangioendothelioma (HEH) is a rare, low-grade malignant neoplasm of endothelial origin, with an unpredictable clinical course and prognosis.
  • No standard therapeutic strategies are still available for HEH, due to the infrequency of the disease and to its variable natural history that limit the identification of the most effective treatment.
  • In the absence of metastatic disease, surgical resection or liver transplantation represent the treatment of choice for HEH, while several antineoplastic agents have been proposed in the presence of metastatic nonresectable disesase.
  • Herein, we describe the biological characterization and the clinical course of a primary HEH progressively responsive to treatment with intermediate doses of interferon-alpha (IFN)-alpha2a.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hemangioendothelioma, Epithelioid / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy. Neovascularization, Pathologic / prevention & control
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD31 / analysis. Antigens, CD34 / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Receptors, Cell Surface / analysis. Recombinant Proteins. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550144.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / ENG protein, human; 0 / Interferon-alpha; 0 / Receptors, Cell Surface; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


21. Kanizaj TF, Cvrlje VC, Mrzljak A, Kardum-Skelin I, Sustercić D, Segro D, Gustin D, Kocman B: Epitheloid hemangioendothelioma in patient with liver transplantation. Coll Antropol; 2010 Mar;34(1):177-80
Hazardous Substances Data Bank. METHYLENE BLUE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epitheloid hemangioendothelioma in patient with liver transplantation.
  • Malignant hepatic epithelioid hemangioendothelioma (HEH) is a rare malignant tumor of vascular origin with unknown aetiology and a variable natural course.
  • At the time of diagnosis, most patients present with multifocal tumours lesions that involve both liver lobes.
  • From the therapeutic aspect, liver resection (LRx), liver transplantation (LTx), chemotherapy, radiotherapy, and/or immunotherapy have been used in the treatment of patients with HEH.
  • However, because of the rarity of this tumor and its unpredictable natural history, it is impossible to assess the effectiveness of these respective therapies.
  • In this report, our objective was to present clinical aspects, diagnostic options, therapeutic modalities, and the clinical outcome of single patient with LTx because of this rare tumor.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / pathology. Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Liver Transplantation

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432748.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / May-Grunwald Giemsa; T42P99266K / Methylene Blue; TDQ283MPCW / Eosine Yellowish-(YS)
  •  go-up   go-down


22. Park EA, Seo JW, Lee SW, Choi HY, Lee SJ: Infantile hemangioendothelioma treated with high dose methylprednisolone pulse therapy. J Korean Med Sci; 2001 Feb;16(1):127-9
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile hemangioendothelioma treated with high dose methylprednisolone pulse therapy.
  • Infantile hemangioendothelioma is a severe disease with a high mortality.
  • We report that high doses of methylprednisolone pulse therapy improved symptoms and signs of infantile hemangioendothelioma in a male neonate, and completely resolved the hepatic and cutaneous hemangioendothelioma on follow up.
  • [MeSH-major] Hemangioendothelioma / drug therapy. Liver Neoplasms / drug therapy. Methylprednisolone / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11289392.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC3054580
  •  go-up   go-down


23. Chartier A, Barbier C, Thumerelle C, Santos C, Desfachelles AS, Devisme L, Deschildre A: [Hypertrophic pulmonary osteo-arthropathy revealed by a pulmonary epithelioid hemangioendothelioma in a 15-year-old girl]. Arch Pediatr; 2003 Jul;10(7):626-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypertrophic pulmonary osteo-arthropathy revealed by a pulmonary epithelioid hemangioendothelioma in a 15-year-old girl].
  • Pulmonary epithelioid hemangioendothelioma is a rare vascular tumor of the lung, that may be revealed by hypertrophic pulmonary osteo-arthropathy.
  • A hypertrophic pulmonary osteo-arthropathy due to a paraneoplastic syndrome associated with lung epithelioid hemangioendothelioma was diagnosed.
  • Despite surgical resection and chemotherapy, the patient died 6 months later.
  • Diagnosis is confirmed by long bones proliferative periostitis on standard X-ray examination.
  • Pulmonary epithelioid hemangioendothelioma is a rare vascular malignant tumor, that spreads from the vascular pulmonary or hepatic tissues.
  • In the absence of a chronic cardiorespiratory disease, the diagnosis of a pulmonary hypertrophic osteo-arthropathy in childhood should prompt the search for a tumoral cause.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / complications. Hemangioendothelioma, Epithelioid / diagnosis. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Osteoarthropathy, Primary Hypertrophic / etiology
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12907072.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Wen CC, Munarriz R, Goldstein I: Three-chamber priapism in a patient with primary epithelioid hemangioendothelioma of penis. Urology; 2004 Jul;64(1):156-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-chamber priapism in a patient with primary epithelioid hemangioendothelioma of penis.
  • Cavernosal biopsies revealed epithelioid hemangioendothelioma, and the metastatic workup found hepatic and pulmonary lesions.
  • [MeSH-major] Diagnostic Errors. Hemangioendothelioma, Epithelioid / complications. Hemangioendothelioma, Epithelioid / diagnosis. Penile Neoplasms / complications. Penile Neoplasms / diagnosis. Priapism / etiology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Biopsy. False Negative Reactions. Fatal Outcome. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Paclitaxel / therapeutic use. Penile Induration / diagnosis. Urination Disorders / etiology

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • Genetic Alliance. consumer health - Priapism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15245958.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Mucha K, Foroncewicz B, Zieniewicz K, Nyckowski P, Krawczyk M, Cyganek A, Paczek L: Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years' observation. Transplant Proc; 2006 Jan-Feb;38(1):231-3
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient with liver epithelioid hemangioendothelioma treated by transplantation: 3 years' observation.
  • Epithelioid hemangioendothelioma (EHE) is a rare neoplasm of vascular origin, but unknown etiology that occurs in the liver, lungs and other organs.
  • Its hepatic form (HEHE) generally behaves as a low-grade malignant tumor with a slowly progressive phenotype.
  • Surgical resection or liver transplantation (OLT) has been recommended after diagnosis.
  • We present a 30-year-old woman with primary HEHE of the liver treated by OLT in 2002.
  • Her medical history started 3 years prior when an abdominal ultrasound examination revealed multiple focal changes in the liver.
  • The histopathological diagnosis from a needle biopsy was carcinoma cholangiogenes desmoplasticum.
  • For 2 years the patient was treated with chemotherapy combinations.
  • To explain the lack of efficacy of chemotherapy, a laparoscopic biopsy was performed and HEHE diagnosed.
  • After 3 years observation the patient presented with good liver function and no signs of tumor recurrence.
  • We concluded that immunohistochemical staining for characteristic endothelial cell markers may facilitate the correct diagnosis of HEHE.
  • After diagnosis, OLT followed by immunosuppressive therapy, consisting of basiliximab, corticoids, low doses of tacrolimus and temporary administration of rapamycin, may be safe and effective.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Treatment Outcome


26. Szavay PO, Wermes C, Fuchs J, Schrappe M, Flemming P, von Schweinitz D: Effective treatment of infantile choriocarcinoma in the liver with chemotherapy and surgical resection: a case report. J Pediatr Surg; 2000 Jul;35(7):1134-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of infantile choriocarcinoma in the liver with chemotherapy and surgical resection: a case report.
  • Infantile choriocarcinoma of the liver is an extremely rare entity, and outcome has been fatal in almost all published cases.
  • To the authors' knowledge, this is the first report on successful treatment with preoperative chemotherapy.
  • A 10-week-old girl presented with a large liver tumor, ovarian cysts, cardiac insufficiency, progressive hemolytic anemia, and thrombocytopenia.
  • Ultrasound scan and magnetic resonance tomography (MRT) showed the typical pattern of infantile hemangioendothelioma.
  • An emergency laparotomy was performed because of increasing cardiac insufficiency with ligation of the right hepatic artery, tumor biopsy, and subtotal resection of the ovarian cysts.
  • Histology findings showed a choriocarcinoma of the liver and corpus luteum cysts of the ovaries.
  • Chemotherapy was initiated with etoposide and cisplatin.
  • When x-ray examination showed development of lung metastases, chemotherapy was intensified with etoposide, cisplatin, and ifosfamid according to the German Study Group of Extracranial Nontesticular Malignant Germ Cell Tumors in Childhood and Adolescence (MAKEI-96).
  • After the fourth course, a complete tumor resection was achieved by an extended right hemihepatectomy with adjuvant chemotherapy being administered after the operation.
  • The authors' experience shows that chemotherapy is effective for preoperative tumor reduction.
  • [MeSH-major] Choriocarcinoma / drug therapy. Choriocarcinoma / surgery. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Infant, Newborn. Remission Induction

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10917316.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Sharif K, English M, Ramani P, Alberti D, Otte JB, McKiernan P, Gosseye S, Jenney M, de Ville de Goyet J: Management of hepatic epithelioid haemangio-endothelioma in children: what option? Br J Cancer; 2004 Apr 19;90(8):1498-501
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of hepatic epithelioid haemangio-endothelioma in children: what option?
  • Hepatic epithelioid haemangio-endothelioma (HEHE) is an endothelium-derived tumour of low-to-medium grade malignancy.
  • It is predominantly seen in adults and is unresponsive to chemotherapy.
  • Liver transplantation is an accepted indication when the tumour is unresectable.
  • Hepatic epithelioid haemangio-endothelioma is very rare in children and results after transplantation are not reported.
  • The first had successful resection followed by chemotherapy and is alive, without disease 3 years after diagnosis.
  • Two children who had progressive disease with ifosfamide-based chemotherapy have had a reduction in clinical symptoms and stabilisation of disease up to 18 and 24 months after the use of platinum-based chemotherapy.
  • Ifosfamide-based chemotherapy was not effective.
  • Further studies are necessary to confirm if HEHE progression in children may be influenced by platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangioendothelioma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Alkylating / therapeutic use. Child. Child, Preschool. Female. Humans. Ifosfamide / therapeutic use. Liver Transplantation. Male. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1989 Sep;15(3):225-37 [2807182.001]
  • [Cites] Eur Respir J. 1999 Jul;14(1):237-8 [10489858.001]
  • [Cites] Hum Pathol. 1984 Sep;15(9):839-52 [6088383.001]
  • [Cites] Transplantation. 2002 Jul 15;74(1):128-30 [12134111.001]
  • [Cites] J Clin Gastroenterol. 2001 May-Jun;32(5):431-4 [11319317.001]
  • [Cites] Liver Transpl. 2000 Nov;6(6 Suppl 2):S23-9 [11084081.001]
  • [Cites] Pathologe. 1999 Nov;20(6):345-50 [10591953.001]
  • [Cites] Liver Transpl Surg. 1999 Nov;5(6):526-31 [10545542.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):263-70 [9060595.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2318-27 [8941001.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):483-7 [8591077.001]
  • [Cites] J Comput Assist Tomogr. 1992 May-Jun;16(3):420-4 [1592925.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):999-1008 [2596622.001]
  • [Cites] Gastroenterology. 1988 Jun;94(6):1447-53 [3282968.001]
  • (PMID = 15083175.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ PMC2409708
  •  go-up   go-down


28. Maisonnette F, Hardemann S, Abita T, Durand-Fontanier S, Valleix D, Descottes B: [Hepatic haemangioendothelioma: case report and review of literature]. Ann Chir; 2006 Feb;131(2):115-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatic haemangioendothelioma: case report and review of literature].
  • We discovered many hepatic lesions.
  • After reexamination of histology we discovered hepatic haemangioendothelioma.
  • The patient died 18 month after diagnosis although chemotherapy.
  • [MeSH-major] Hemangioendothelioma. Liver Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246294.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 11
  •  go-up   go-down


29. Berber E, Ari E, Herceg N, Siperstein A: Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc; 2005 Dec;19(12):1613-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes.
  • BACKGROUND: There is increasing experience with laparoscopic radiofrequency ablation for the treatment of patients with hepatic metastasis from colorectal and neuroendocrine cancer and those with hepatocellular cancer.
  • Little is known about the outcomes for patients with other tumor types.
  • METHODS: Between January 1996 and March 2005, 517 patients with 1,500 primary and metastatic liver tumors underwent laparoscopic radiofrequency ablation.
  • Among these, 53 patients (10%) had cancers other than the colorectal, neuroendocrine, or hepatocellular types including sarcoma (n = 18), breast cancer (n = 10), esophagus cancer (n = 4), melanoma (n = 4), lung cancer (n = 3), ovarian cancer (n = 2), pancreas cancer (n = 2), unknown primary cancer (n = 2), cholangiocarcinoma (n = 2), rectal squamous cancer (n = 2), renal cancer (n = 2), papillary thyroid cancer (n = 1), and hemangioendothelioma (n = 1).
  • Unlike the criteria for treatment of the more usual tumor types, these patients had a diagnosis of liver-exclusive disease, as diagnosed by preoperative imaging.
  • They also had failed chemotherapy.
  • RESULTS: The 53 patients underwent ablation of 192 lesions, with 8 patients undergoing repeat treatment.
  • Complications included one postoperative hemorrhage, one liver abscess, and one wound infection.
  • CONCLUSION: Laparoscopic radiofrequency ablation can safely and effectively treat hepatic metastasis of these unusual tumor types.
  • The authors believe that this heterogeneous group of patients, selected for their unusual presentation of liver-exclusive disease, may benefit from cytoreduction of their tumor by laparoscopic radiofrequency ablation when other treatment methods have failed.
  • [MeSH-major] Catheter Ablation / methods. Laparoscopy. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2000 Apr;14(4):400-5 [10790563.001]
  • [Cites] World J Surg. 2002 Aug;26(8):985-90 [12016479.001]
  • [Cites] Surg Endosc. 2005 May;19(5):710-4 [15759186.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):201-5 [9496513.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1009-14 [10551746.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):72-5 [7740813.001]
  • [Cites] J Gastrointest Surg. 1998 Mar-Apr;2(2):151-5 [9834411.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):950-5 [11485537.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):379-80 [11352313.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1120-5 [8630886.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):106-13 [10761788.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):1-8 [10400029.001]
  • [Cites] Oncologist. 2003;8(3):241-51 [12773746.001]
  • [Cites] Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5 [9426432.001]
  • [Cites] Ann Surg. 1995 Apr;221(4):392-7 [7726675.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Arch Surg. 2001 Aug;136(8):864-9 [11485520.001]
  • [Cites] J Vasc Interv Radiol. 1999 Jul-Aug;10(7):907-16 [10435709.001]
  • [Cites] J Surg Res. 1999 Nov;87(1):114-21 [10527712.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • [Cites] Ann Thorac Surg. 2003 Jul;76(1):291-3 [12842567.001]
  • (PMID = 16247574.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. O'Grady JG: Treatment options for other hepatic malignancies. Liver Transpl; 2000 Nov;6(6 Suppl 2):S23-9
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for other hepatic malignancies.
  • 2. Multimodality approaches involving various combinations of chemotherapy, irradiation, and surgery increasingly are being used to treat cholangiocarcinoma.
  • 3. The role of liver transplantation in the management of cholangiocarcinoma is limited by the perception that it is inappropriate to use scarce organs when 5-year survival rates are 25%.
  • 4. Liver transplantation is an important intervention in patients with tumors that remain unresectable after chemotherapy.
  • The role of liver transplantation in patients with extrahepatic disease that responds to chemotherapy is controversial.
  • Careful timing of surgery is required to avoid secondary drug resistance.
  • 5. Liver transplantation has been successfully applied to a range of rare hepatic malignancies, but small numbers preclude strong recommendations on the appropriateness of this practice.
  • [MeSH-major] Liver Neoplasms / therapy. Liver Transplantation
  • [MeSH-minor] Bile Duct Neoplasms / therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / surgery. Cholangiocarcinoma / therapy. Combined Modality Therapy. Cystadenocarcinoma / therapy. Genetic Therapy. Hemangioendothelioma / therapy. Hemangiosarcoma / therapy. Hepatoblastoma / therapy. Humans. Neuroendocrine Tumors / therapy. Palliative Care

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11084081.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 26
  •  go-up   go-down


31. Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, Mulligan D, Nguyen J, Rosen C, Reid-Lombardo KM: Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? HPB (Oxford); 2010 Oct;12(8):546-53
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?
  • BACKGROUND: Hepatic epithelioid haemangioendothelioma (HEH) is a rare vascular neoplasm with unpredictable clinical behaviour.
  • AIM: To compare overall survival (OS) and disease-free survival (DFS) between liver resection (LR) and orthotopic liver transplantation (OLT) for the treatment of HEH.
  • Treatment included LR (n= 11), OLT (n= 11), chemotherapy (n= 5) and no treatment (n= 3).
  • CONCLUSION: LR and OLT achieve comparable results in the treatment of HEH.
  • Metastases may not be a contraindication to surgical treatment.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Palliative Care. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Outcome. United States. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Hepato-Pancreato-Biliary Association.
  • [Cites] Liver Transpl Surg. 1999 Nov;5(6):526-31 [10545542.001]
  • [Cites] Arch Surg. 2009 Nov;144(11):1035-9 [19917940.001]
  • [Cites] Hum Pathol. 1984 Sep;15(9):839-52 [6088383.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;404(3):275-87 [6437065.001]
  • [Cites] J Hepatol. 1986;2(3):441-9 [3522725.001]
  • [Cites] Pathology. 1986 Oct;18(4):459-62 [3822523.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2079-84 [3052779.001]
  • [Cites] J Hepatol. 1989 Jan;8(1):99-106 [2646369.001]
  • [Cites] Histopathology. 1989 Sep;15(3):225-37 [2807182.001]
  • [Cites] Am J Surg Pathol. 1989 Dec;13(12):999-1008 [2596622.001]
  • [Cites] Am J Gastroenterol. 1992 Jun;87(6):797-800 [1534200.001]
  • [Cites] Surgery. 1992 May;111(5):518-26 [1598671.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Pathol Int. 1999 Jun;49(6):547-52 [10469398.001]
  • [Cites] Transplantation. 2005 Sep 27;80(1 Suppl):S109-12 [16286886.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(2):167-71 [16547680.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):439-41 [16648050.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2108-21 [17019735.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1391-6 [17315167.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):949-57; discussion 957 [18043096.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):110-6 [17710508.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):432-7 [18792957.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):970-81 [7093931.001]
  • (PMID = 20887322.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2997660
  •  go-up   go-down


32. Ekinci S, Karnak I, Tanyel FC, Senocak ME, Kutluk T, Büyükpamukçu M, Büyükpamukçu N: Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors. Pediatr Surg Int; 2006 Mar;22(3):228-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors.
  • Hepatic resection is the main treatment modality for hepatic tumors in childhood.
  • The aim of this study is to report our experience in hepatic lobectomy, which is relatively rare procedure in childhood.
  • Medical records of 25 patients who underwent hepatic lobectomy between January 1977 and June 2002 were reviewed retrospectively.
  • Age, gender, diagnosis, physical examination findings, results of preoperative laboratory investigations, radiological examination, resectability criteria, preoperative biopsies, chemotherapies, radiotherapies, postoperative pathological results, incisions, operation technique, intraoperative transfusions, drains used, antibiotic prophylaxes, and intraoperative and postoperative complications were evaluated for all patients.
  • Out of 25 patients with hepatic tumor seven patients with hepatoblastoma and four patients with hepatocellular carcinoma were given 5.7 +/- 0.3 cycles of chemotherapy before the operation.
  • Pathological examination of resected tumors revealed hepatoblastoma (n=11), mesenchymal hamartoma (n = 5), hepatocellular carcinoma (n = 4), hemangioendothelioma (n=1), malignant mesenchymal tumor (n = 1), hemangioma (n = 1), cyst adenoma (n = 1), and metastasis of cellular mesoblastic nephroma (n = 1).
  • Hepatic lobectomy is a major operation, which is feasible yielding curative results in children.
  • Safe hepatic resections with acceptable blood loss can be performed by a technique relying on good anatomic dissection and surgical control.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatr Surg Int. 2006 Aug;22(8):695
  • [Cites] Eur Urol. 1997;32(2):194-7 [9286653.001]
  • [Cites] J Pediatr Surg. 1991 Nov;26(11):1326-30 [1812268.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):386-91 [7796018.001]
  • [Cites] Ann Thorac Surg. 1991 May;51(5):717-21; discussion 721-2 [1850976.001]
  • [Cites] J Pediatr Surg. 1984 Oct;19(5):523-6 [6094781.001]
  • [Cites] Surg Gynecol Obstet. 1957 Sep;105(3):310-8 [13467662.001]
  • [Cites] J Surg Res. 1996 Feb 15;61(1):183-9 [8769964.001]
  • [Cites] Surgery. 1998 Apr;123(4):407-14 [9551066.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):512-37 [6303939.001]
  • [Cites] Chirurgie. 1986;112(5):337-42 [3608701.001]
  • [Cites] World J Surg. 1982 Jan;6(1):3-9 [7090393.001]
  • [Cites] J Pediatr Surg. 2000 Oct;35(10 ):1459-61 [11051151.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):330-42 [9015180.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1080-3; discussion 1083-4 [1328586.001]
  • [Cites] AJR Am J Roentgenol. 1993 Sep;161(3):572-3 [8352107.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] J Pediatr Surg. 2001 May;36(5):755-9 [11329582.001]
  • (PMID = 16395609.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


33. Hertl M, Cosimi AB: Liver transplantation for malignancy. Oncologist; 2005 Apr;10(4):269-81
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for malignancy.
  • Liver transplantation for hepatic malignancies has emerged from an exotic and desperate approach to a well-documented and proven treatment modality for these unfortunate patients.
  • Currently, <10% of all liver transplants performed are for hepatocellular cancer (HCC).
  • Similarly, liver transplantation for HCC in the adult population yields good results for patients whose tumor masses do not exceed the Milan criteria.
  • It remains to be determined whether patients with more extensive tumors can be reliably selected to benefit from the procedure.
  • Epitheloid hemangioendothelioma is also an appropriate indication for liver transplantation, unlike angiosarcoma.
  • Metastatic liver disease is not an indication for liver transplantation, with the exception of cases in which the primary is a neuroendocrine tumor, for which liver transplantation can result in long-term survival and even cure in a number of patients.
  • And finally, while gallbladder cancers are never an indication for liver transplantation, rare cases of cholangiocellular cancer might qualify if aggressive combination therapies, including chemotherapy and radiotherapy followed by OLT, are carried through.
  • Survival in these selected patients can approach that for patients with cholestatic liver disease.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Hemangioendothelioma, Epithelioid / mortality. Hemangioendothelioma, Epithelioid / pathology. Hemangioendothelioma, Epithelioid / surgery. Hepatoblastoma / mortality. Hepatoblastoma / pathology. Hepatoblastoma / surgery. Humans. Medical Oncology / trends. Neoplasm Metastasis. Patient Selection. Survival Rate. Treatment Outcome. Waiting Lists

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821247.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


34. Grossman EJ, Millis JM: Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl; 2010 Aug;16(8):930-42
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature.
  • Orthotopic liver transplantation (OLT) is currently incorporated into the treatment regimens for specific nonhepatocellular malignancies.
  • Hepatic involvement from neuroendocrine tumors can be treated with OLT when metastases are unresectable or for palliation of medically uncontrollable symptoms.
  • Hepatic epithelioid hemangioendothelioma is a rare tumor of vascular origin.
  • Hepatoblastoma is the most common primary hepatic malignancy in children.
  • There exist subtle differences in the timing of chemotherapy between US and European centers; however, the long-term survival rate after transplantation ranges from 66% to 77%.
  • Fibrolamellar hepatocellular carcinoma is a distinct liver malignancy best treated by surgical resection.
  • In the treatment of either primary or metastatic hepatic sarcomas, unacceptable survival and recurrence rates currently prohibit the use of OLT.
  • [MeSH-major] Liver Neoplasms / therapy. Liver Transplantation / methods
  • [MeSH-minor] Aged. Cholangiocarcinoma / therapy. Hemangioendothelioma / therapy. Hepatoblastoma / therapy. Humans. Immunosuppressive Agents / therapeutic use. Liver / pathology. Medical Oncology / methods. Middle Aged. Neoplasm Metastasis. Neuroendocrine Tumors / therapy. Sarcoma / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AASLD.
  • (PMID = 20677284.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


35. Emre S, McKenna GJ: Liver tumors in children. Pediatr Transplant; 2004 Dec;8(6):632-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver tumors in children.
  • Primary hepatic neoplasms in children are relatively infrequent, accounting for between 0.5 and 2.0% of all pediatric neoplasms.
  • They are clinically relevant tumors however as two thirds of them are malignant.
  • The therapy of these tumors has evolved over time and it currently involves a combination of surgery, adjuvant and neoadjuvant chemotherapy and possible transplantation.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / therapy. Child. Hamartoma / diagnosis. Hamartoma / therapy. Hemangioendothelioma / diagnosis. Hemangioendothelioma / therapy. Hemangiosarcoma / diagnosis. Hepatoblastoma / pathology. Hepatoblastoma / therapy. Humans. Neoplasm Staging. Sarcoma / diagnosis. Sarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15598339.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 66
  •  go-up   go-down


36. Makin E, Davenport M: Fetal and neonatal liver tumours. Early Hum Dev; 2010 Oct;86(10):637-42
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal and neonatal liver tumours.
  • Liver tumours are rare in children and account for about 5% of all tumours in the fetus and newborn.
  • While the diagnosis can be suspected antenatally (by ultrasound and MR scan), a precise diagnosis is often difficult due to the complexity of the tumours.
  • Treatment options may include watchful waiting, surgical resection, hepatic artery embolisation/ligation and chemotherapy.
  • [MeSH-major] Fetal Diseases / diagnosis. Hamartoma / diagnosis. Hemangioendothelioma / diagnosis. Hepatoblastoma / diagnosis. Liver Neoplasms / diagnosis. Mesoderm / pathology
  • [MeSH-minor] Female. Humans. Infant, Newborn. Liver / surgery. Magnetic Resonance Imaging. Male. Practice Guidelines as Topic. Ultrasonography, Prenatal. Watchful Waiting

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20956063.001).
  • [ISSN] 1872-6232
  • [Journal-full-title] Early human development
  • [ISO-abbreviation] Early Hum. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


37. Wiederkehr JC, Coelho IM, Avilla SG, e Silva EM, Schuller S, Ouno DD, Wiederkehr BA, Polimeni M: Prevalence of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients. Transplant Proc; 2010 Mar;42(2):521-2
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients.
  • OBJECTIVE: The objective of this study was to identify the incidence of posttransplantation lymphoproliferative disease (PTLD) among children within 1 year after liver transplantation.
  • METHODS: This retrospective review analyzed information in medical charts of pediatric (younger than 18 years of age) recipients of liver transplants between September 2000 and December 2007.
  • RESULTS: Seventy-one patients underwent a liver transplantation and 7 (9.85%) developed PTLD.
  • Indications that led the children to have their transplantation were 1 case of hemangioendothelioma, 1 case of autoimmune hepatic cirrhosis, 1 case of alpha-1-antitrypsin deficiency, and 4 cases of biliary atresia.
  • The median time from the first symptoms to the initial treatment was 9.7 days.
  • The standard treatment was withdrawal of immunosuppression and close observation of tacrolimus levels and liver function tests associated with antiviral drugs and chemotherapy.
  • [MeSH-major] Liver Transplantation / adverse effects. Lymphoproliferative Disorders / epidemiology. Postoperative Complications / epidemiology
  • [MeSH-minor] Biliary Atresia / surgery. Child. Child, Preschool. Epstein-Barr Virus Infections / surgery. Female. Humans. Immunosuppressive Agents / therapeutic use. Infant. Liver Diseases / classification. Liver Diseases / surgery. Male. Prevalence. Retrospective Studies. Splenomegaly / etiology. Tacrolimus / therapeutic use. alpha 1-Antitrypsin Deficiency / surgery

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20304183.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


38. Almogy G, Lieberman S, Gips M, Pappo O, Edden Y, Jurim O, Simon Slasky B, Uzieli B, Eid A: Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre. Eur J Surg Oncol; 2004 May;30(4):421-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of surgical resections for primary liver sarcoma in adults: results from a single centre.
  • BACKGROUND: Primary hepatic sarcoma is a rare tumour with a poor prognosis.
  • METHODS: From 1997 to 2002 eight patients had liver resection for primary sarcoma of the liver at our institution.
  • The clinical characteristics, imaging findings, surgical procedures, adjuvant therapy and outcome were retrospectively reviewed.
  • There were two patients each with angiosarcoma (AS), leiomyosarcoma (LMS), and undifferentiated embryonal sarcoma (UES), one patient with epithelioid hemangioendothelioma (EHE) and one patient with malignant peripheral nerve sheath sarcoma (PNSS).
  • Preoperative diagnosis of a primary liver sarcoma was made in 7/8 cases, either by fine needle aspiration (n = 5) or angiography (n = 2).
  • Two patients developed complications and there was one death.
  • Systemic chemotherapy led to tumour regression in both patients with UES which enabled a second hepatic resection.
  • CONCLUSIONS: The majority of patients with primary liver sarcoma present with right upper quadrant pain, fever and a liver mass.
  • Differentiating the rare primary liver sarcoma from the much more common hepatocellular carcinoma (HCC) may aid in planning therapy.
  • Liver resection combined with adjuvant chemotherapy are the mainstays of treatment for UES in the adult.
  • [MeSH-major] Liver Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Hepatectomy / methods. Humans. Length of Stay. Liver Function Tests. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15063896.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Stringer MD: The role of liver transplantation in the management of paediatric liver tumours. Ann R Coll Surg Engl; 2007 Jan;89(1):12-21
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of liver transplantation in the management of paediatric liver tumours.
  • In recent years, considerable progress has been made in the treatment of children with hepatoblastoma largely due to effective pre-operative chemotherapy.
  • Total hepatectomy and liver transplantation has emerged as an effective treatment for the small proportion of children with unresectable hepatoblastoma limited to the liver.
  • In contrast, the results of liver transplantation in children with hepatocellular cancer remain poor because these tumours are usually advanced with evidence of major vascular invasion and/or extrahepatic spread at the time of presentation.
  • An exception is those children in whom the hepatocellular carcinoma is detected during surveillance of chronic liver disease - they typically have smaller tumours and frequently have a good prognosis after liver transplantation.
  • The role of liver transplantation in children with other primary hepatic malignancies remains uncertain because experience is very limited.
  • Liver transplantation is rarely needed in the management of children with benign liver tumours but, if other treatments have failed, it can be a life-saving intervention.
  • [MeSH-major] Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Child. Hamartoma / mortality. Hamartoma / surgery. Hemangioendothelioma, Epithelioid. Hepatoblastoma / mortality. Hepatoblastoma / surgery. Humans. Liver Diseases / mortality. Liver Diseases / surgery. Neoplasms, Muscle Tissue / mortality. Neoplasms, Muscle Tissue / surgery. Sarcoma / mortality. Sarcoma / surgery. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1999 Jan;34(1):98-105; discussion 105-6 [10022152.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] Pediatr Dev Pathol. 2004 Sep-Oct;7(5):527-32 [15547777.001]
  • [Cites] J Pediatr. 2005 Feb;146(2):204-11 [15689909.001]
  • [Cites] Liver Transpl. 2005 May;11(5):494-6 [15838915.001]
  • [Cites] Surgery. 1991 Feb;109(2):208-13 [1846984.001]
  • [Cites] Eur J Cancer. 2005 May;41(7):1031-6 [15862752.001]
  • [Cites] J Pediatr Surg. 2005 Jul;40(7):1185-7 [16034768.001]
  • [Cites] Pediatr Transplant. 2005 Oct;9(5):557-65 [16176410.001]
  • [Cites] J Pediatr Surg. 2005 Nov;40(11):1681-90 [16291152.001]
  • [Cites] Clin Transplant. 2005 Dec;19(6):721-5 [16313316.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):795-804 [10839879.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1418-25 [10899656.001]
  • [Cites] J Pediatr Surg. 2000 Sep;35(9):1294-9 [10999682.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1845-53 [11042582.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3819-28 [11078495.001]
  • [Cites] Ann Surg. 2000 Dec;232(6):777-85 [11088072.001]
  • [Cites] Transpl Int. 2000;13 Suppl 1:S406-9 [11112043.001]
  • [Cites] Semin Pediatr Surg. 2000 Nov;9(4):196-208 [11112837.001]
  • [Cites] J Pediatr Surg. 2001 Mar;36(3):436-9 [11226990.001]
  • [Cites] Surgery. 2001 Jun;129(6):757-60 [11391376.001]
  • [Cites] Pediatr Surg Int. 2001 Jul;17(5-6):378-81 [11527170.001]
  • [Cites] Transplantation. 2002 Jan 15;73(1):90-2 [11792985.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):252-7 [11815984.001]
  • [Cites] J Pediatr Surg. 2002 Feb;37(2):240-5 [11819207.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1111-20 [11920482.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2789-97 [12065555.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2798-804 [12065556.001]
  • [Cites] J Pediatr Surg. 2002 Jul;37(7):986-9 [12077755.001]
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1419-23 [12378446.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):113-6; discussion 116-7 [12461796.001]
  • [Cites] J Pediatr Surg. 2006 Jan;41(1):182-6 [16410130.001]
  • [Cites] Pediatr Surg Int. 2006 Mar;22(3):282-5 [16328328.001]
  • [Cites] Pathologe. 1999 Nov;20(6):345-50 [10591953.001]
  • [Cites] Med Pediatr Oncol. 2000 Feb;34(2):132-5 [10657875.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):303-7; discussion 308 [10693685.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):2006-12 [12673731.001]
  • [Cites] J Pediatr Surg. 2003 Jul;38(7):1108-11 [12861553.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):411-21 [14746860.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):74-83 [14752798.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):131-3 [14760656.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):121-3 [14767204.001]
  • [Cites] Pediatr Dev Pathol. 2003 Nov-Dec;6(6):552-7 [15018455.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1498-501 [15083175.001]
  • [Cites] J Pediatr Surg. 2004 May;39(5):721-5 [15137006.001]
  • [Cites] Pediatr Transplant. 2004 Oct;8(5):517-21 [15367291.001]
  • [Cites] J Pediatr Surg. 1981 Jun;16(3):339-42 [6265620.001]
  • [Cites] Pediatr Radiol. 1981;11(1):42-5 [7196009.001]
  • [Cites] Pediatr Radiol. 1984;14(6):433-5 [6504606.001]
  • [Cites] Br J Surg. 1990 Jan;77(1):21-6 [2302506.001]
  • [Cites] Paediatr Perinat Epidemiol. 1990 Jul;4(3):276-89 [2374747.001]
  • [Cites] Surgery. 1991 Oct;110(4):726-34; discussion 734-5 [1656538.001]
  • [Cites] J Pediatr Surg. 1992 Mar;27(3):292-6; discussion 297 [1323649.001]
  • [Cites] Transpl Int. 1993 Mar;6(2):95-8 [8383496.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1994 Jul;19(1):114-7 [7965461.001]
  • [Cites] Med Pediatr Oncol. 1995 Jan;24(1):58-60 [7968795.001]
  • [Cites] J Pediatr Surg. 1994 Oct;29(10):1319-22 [7807316.001]
  • [Cites] J Pediatr Surg. 1994 Nov;29(11):1465-9 [7844722.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):153-6 [7848084.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):386-91 [7796018.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):693-9 [8594428.001]
  • [Cites] Transplant Proc. 1996 Aug;28(4):2393-4 [8769264.001]
  • [Cites] J Pediatr Surg. 1996 Jun;31(6):835-9 [8783117.001]
  • [Cites] J Pediatr Surg. 1996 Jun;31(6):840-2 [8783118.001]
  • [Cites] J Pediatr Surg. 1996 Nov;31(11):1563-7 [8943124.001]
  • [Cites] Med Pediatr Oncol. 1997 Feb;28(2):139-43 [8986151.001]
  • [Cites] J Pediatr Surg. 1996 Dec;31(12):1729-32 [8987004.001]
  • [Cites] Pediatr Surg Int. 1997 Apr;12(4):266-70 [9099643.001]
  • [Cites] J Pediatr Surg. 1998 Sep;33(9):1350-4 [9766351.001]
  • (PMID = 17316514.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  • [Other-IDs] NLM/ PMC1963524
  •  go-up   go-down


40. Albert A, Cruz O, Montaner A, Vela A, Badosa J, Castañón M, Morales L: [Congenital solid tumors. A thirteen-year review]. Cir Pediatr; 2004 Jul;17(3):133-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an interesting group of tumors because their type, relative incidence, natural history and response to treatment differ from those seen in older children.
  • There were 8 teratomas (3 sacrocoxigeal, 1 retroperitoneal, 1 in the CNS, 1 orbitary and two oronasal), two hepatic tumors (1 hepatoblastoma, 1 hemangioendothelioma, two CNS tumors, two giant nevus (one on a hamartoma), and one each Wilms tumor, infantile fibrosarcoma and myofibroblastic tumor.
  • Treatment was surgical resection alone in 17 cases (68%) and surgery + chemotherapy in 8 (32%) (5 neuroblastomas, one CNS tumor, one Wilms tumor and one presacral teratoma who developed a yolk sac tumor); 3 patients died (11%): one at surgery, one of tumoural airway obstruction at birth and one with craniopharyngioma.
  • Among the 14 tumors that were initially not malignant, two can be locally agressive, one was an immature teratoma, the giant nevus with hamartoma developed in situ melanoma, the other nevus had meningeal melanosis with hydrocephalus, and one mature presacral teratoma developed a yolk sac tumor.
  • CONCLUSIONS: Diagnosis of congenital tumors is performed earlier in recent years due to the wide use of prenatal ultrasound.
  • Complete surgical excision is the treatment of choice, most cases not need adjuvant chemotherapy.
  • We ought to pass this message on to our colleagues in prenatal diagnosis, so parents get reliable information.
  • [MeSH-major] Central Nervous System Neoplasms / congenital. Kidney Neoplasms / congenital. Liver Neoplasms / congenital. Neuroblastoma / congenital. Skin Neoplasms / congenital. Soft Tissue Neoplasms / congenital. Teratoma / congenital. Wilms Tumor / congenital
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local. Postoperative Complications. Pregnancy. Prenatal Diagnosis. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503950.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Sarialioglu F, Erbay A, Demir S: Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy. Pediatr Blood Cancer; 2010 Dec 15;55(7):1433-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy.
  • [MeSH-major] Drug Resistance, Neoplasm. Hemangioendothelioma / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy. Methylprednisolone / administration & dosage. Propranolol / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Infant. Male

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981697.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 9Y8NXQ24VQ / Propranolol; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


42. Szymik-Kantorowicz S, Partyka L, Dembinska-Kiec A, Zdzienicka A: Vascular endothelial growth factor in monitoring therapy of hepatic haemangioendothelioma. Med Pediatr Oncol; 2003 Mar;40(3):196-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor in monitoring therapy of hepatic haemangioendothelioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Endothelial Growth Factors / blood. Hemangioendothelioma / blood. Hemangioendothelioma / drug therapy. Intercellular Signaling Peptides and Proteins / blood. Interferon-alpha / therapeutic use. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Lymphokines / blood
  • [MeSH-minor] Biomarkers / blood. Drug Monitoring. Humans. Infant. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12518353.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interferon-alpha; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


43. Schmitz R, Heinig J, Klockenbusch W, Kiesel L, Steinhard J: Antenatal diagnosis of a giant fetal hepatic hemangioma and treatment with maternal corticosteroid. Ultraschall Med; 2009 Jun;30(3):223-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antenatal diagnosis of a giant fetal hepatic hemangioma and treatment with maternal corticosteroid.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Dexamethasone / administration & dosage. Hemangioendothelioma / congenital. Hemangioendothelioma / drug therapy. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Liver Neoplasms / congenital. Liver Neoplasms / drug therapy. Ultrasonography, Prenatal / methods
  • [MeSH-minor] Abnormalities, Multiple / ultrasonography. Administration, Oral. Cesarean Section. Embolization, Therapeutic. Female. Follow-Up Studies. Hemodynamics / drug effects. Hemodynamics / physiology. Humans. Infant, Newborn. Male. Pregnancy. Syndrome. Ultrasonography, Doppler. Umbilical Arteries / ultrasonography

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ultraschall Med. 2009 Jun;30(3):226
  • (PMID = 19507116.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down






Advertisement